Loading...

MDWN

MDWD

MEDIWOUND LTD

(MDWD)

2025 6-K

Show Summary

Summary

Insider Share Purchases

19 Aug '25

Q2 Earnings Report

14 Aug '25

Financial Update

21 May '25

Shareholder Meeting Results

15 May '25

Annual Meeting Notice

7 Apr '25

Financial Results Update

19 Mar '25

Clinical Trial Initiation

12 Feb '25

Company Update

8 Jan '25

Shareholder Meeting

19 Dec '24

Board Purchases Shares

16 Dec '24

Quarterly Results

26 Nov '24

Shareholder Meeting Notice

14 Nov '24

FDA Approval Announcement

15 Aug '24

Company Presentation Update

14 Aug '24

Q2 2024 Results

14 Aug '24

Positive Results

5 Aug '24

Funding Announcement

16 Jul '24

Settlement Agreement Update

15 Jul '24

Funding & Collaboration

15 Jul '24

Shareholder Meeting Results

9 Jul '24

Annual Meeting Notice

29 May '24

Financial Report

29 May '24

Financial Report Update

21 Mar '24

Positive Study Results

12 Feb '24

FDA Review Acceptance

9 Jan '24

Company Presentation

8 Jan '24

External Links:

SEC

On February 12, 2025, MediWound Ltd. announced the start of the VALUE Global Phase III trial for its EscharEx treatment aimed at venous leg ulcers. This announcement is significant for the company as it advances their clinical development pipeline.

AI Assistant

MEDIWOUND LTD

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.